Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial
Richard E. Pratley / nature - Nature Medicine, Published online: 08 June 2026; doi:10.1038/s41591-026-04440-4In the phase 2 EMBRAZE study, participants receiving tirzepatide and apitegromab lost less lean mass compared to participants receiving tirzepatide and placebo.
AI Summary: A randomized, double‑blind phase 2 trial found apitegromab helped preserve lean mass in people losing weight on tirzepatide (a GLP‑1–class obesity medication). The drug reduced treatment‑associated muscle wasting without undermining weight loss, positioning apitegromab as a potential adjunct for patients worried about strength and frailty during aggressive metabolic therapy.
Related Stories
Lilly’s triple‑agonist delivers over 28% weight loss in pivotal trial / 24 days
Kailera plans IPO for obesity drug aiming to challenge Zepbound / 2 months
Lilly’s next‑gen GLP‑1 posts compelling Phase 3 weight and A1C results / 2 months
GLP‑1 use linked to lower breast cancer incidence in large cohort / 12 days
Neurocrine buys Soleno Therapeutics for $2.9B to gain Prader‑Willi drug / 2 months
Stem cells show potent promise as a diabetes treatment / 22 days
Lilly’s Zepbound bests Novo’s CagriSema in head‑to‑head obesity trial / 3 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Research Funding, Drug Development, Nutrition, Weight Loss and look for the RSS link.
StackHealth Time Machine